Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company covers the date of March 1, 2018. The report primarily addresses corporate governance changes, specifically the election of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to director compensation and a related party transaction threshold:
- Director Compensation: Annual retainer of $100,000 plus deferred share units valued at $185,000 on the grant date.
- Committee Retainer: Additional annual retainer of $15,000 for the Science and Technology Committee.
- Related Party Transactions: Business and charitable payments to Memorial Sloan-Kettering Cancer Center (MSKCC) accounted for less than 0.3% of MSKCC's revenues for the fiscal year ended December 31, 2017.
Material Changes
The Board of Directors increased its size to twelve members effective March 1, 2018, following the election of Jose Baselga, M.D., Ph.D. Dr. Baselga was appointed as an independent director and assigned to the Science and Technology Committee.
Guidance, Outlook, and Risks
This filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of specific risks or contingencies beyond the standard disclosure of related party transactions. The filing notes that Dr. Baselga was not selected pursuant to any arrangement or understanding with other persons.
Key Facts for Investor Verification
- Confirmation of the new Board size (12 members) and the effective date of Dr. Baselga's appointment (March 1, 2018).
- Verification of Dr. Baselga's independence status under NYSE Listing Standards.
- Review of the specific terms of the compensatory arrangement for non-employee directors.
- Assessment of the nature and volume of ongoing business and charitable payments between Bristol-Myers Squibb and MSKCC.